421 related articles for article (PubMed ID: 27913532)
41. [ALL-XH-99 protocol in the treatment of childhood T-cell acute lymphoblastic leukemia].
Ye QD; Gu LJ; Tang JY; Xue HL; Chen J; Pan C; Chen J; Dong L; Zhou M
Zhonghua Xue Ye Xue Za Zhi; 2009 Jan; 30(1):26-8. PubMed ID: 19563031
[TBL] [Abstract][Full Text] [Related]
42. Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group.
Bader P; Kreyenberg H; Henze GH; Eckert C; Reising M; Willasch A; Barth A; Borkhardt A; Peters C; Handgretinger R; Sykora KW; Holter W; Kabisch H; Klingebiel T; von Stackelberg A;
J Clin Oncol; 2009 Jan; 27(3):377-84. PubMed ID: 19064980
[TBL] [Abstract][Full Text] [Related]
43. Minimal residual disease levels in bone marrow and peripheral blood are comparable in children with T cell acute lymphoblastic leukemia (ALL), but not in precursor-B-ALL.
van der Velden VH; Jacobs DC; Wijkhuijs AJ; Comans-Bitter WM; Willemse MJ; Hählen K; Kamps WA; van Wering ER; van Dongen JJ
Leukemia; 2002 Aug; 16(8):1432-6. PubMed ID: 12145681
[TBL] [Abstract][Full Text] [Related]
44. Prognostic significance of day 14 bone marrow evaluation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia.
Short NJ; Kantarjian HM; Sasaki K; Cortes JE; Ravandi F; Thomas DA; Garcia-Manero G; Khouri I; Kebriaei P; Champlin RE; Pierce S; Issa GC; Konopleva M; Kadia TM; Bueso-Ramos C; Khoury JD; Jain N; O'Brien SM; Jabbour E
Cancer; 2016 Dec; 122(24):3812-3820. PubMed ID: 27508525
[TBL] [Abstract][Full Text] [Related]
45. Prolonged persistence of PCR-detectable minimal residual disease after diagnosis or first relapse predicts poor outcome in childhood B-precursor acute lymphoblastic leukemia.
Steenbergen EJ; Verhagen OJ; van Leeuwen EF; van den Berg H; Behrendt H; Slater RM; von dem Borne AE; van der Schoot CE
Leukemia; 1995 Oct; 9(10):1726-34. PubMed ID: 7564517
[TBL] [Abstract][Full Text] [Related]
46. Linking genomic lesions with minimal residual disease improves prognostic stratification in children with T-cell acute lymphoblastic leukaemia.
La Starza R; Lettieri A; Pierini V; Nofrini V; Gorello P; Songia S; Crescenzi B; Te Kronnie G; Giordan M; Leszl A; Valsecchi MG; Aversa F; Basso G; Biondi A; Conter V; Cazzaniga G; Mecucci C
Leuk Res; 2013 Aug; 37(8):928-35. PubMed ID: 23735857
[TBL] [Abstract][Full Text] [Related]
47. Monitoring minimal residual disease in children with high-risk relapses of acute lymphoblastic leukemia: prognostic relevance of early and late assessment.
Eckert C; Hagedorn N; Sramkova L; Mann G; Panzer-Grümayer R; Peters C; Bourquin JP; Klingebiel T; Borkhardt A; Cario G; Alten J; Escherich G; Astrahantseff K; Seeger K; Henze G; von Stackelberg A
Leukemia; 2015 Aug; 29(8):1648-55. PubMed ID: 25748682
[TBL] [Abstract][Full Text] [Related]
48. [Clinical significance of dynamic monitoring the minimal residual disease in childhood B-lineage acute lymphoblastic leukemia by multiparameter flow cytometry].
Guo DD; Zhao WL; Zhang YL; Pang L; Che L; He HL; Chai YH; Ji ZH; Ji XQ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Dec; 20(6):1346-51. PubMed ID: 23257430
[TBL] [Abstract][Full Text] [Related]
49. End of induction minimal residual disease alone is not a useful determinant for risk stratified therapy in pediatric T-cell acute lymphoblastic leukemia.
Parekh C; Gaynon PS; Abdel-Azim H
Pediatr Blood Cancer; 2015 Nov; 62(11):2040-3. PubMed ID: 25976383
[TBL] [Abstract][Full Text] [Related]
50. Flow cytometric follow-up of minimal residual disease in bone marrow gives prognostic information in children with acute lymphoblastic leukemia.
Björklund E; Mazur J; Söderhäll S; Porwit-MacDonald A
Leukemia; 2003 Jan; 17(1):138-48. PubMed ID: 12529671
[TBL] [Abstract][Full Text] [Related]
51. Transplant Outcomes for Children with T Cell Acute Lymphoblastic Leukemia in Second Remission: A Report from the Center for International Blood and Marrow Transplant Research.
Burke MJ; Verneris MR; Le Rademacher J; He W; Abdel-Azim H; Abraham AA; Auletta JJ; Ayas M; Brown VI; Cairo MS; Chan KW; Diaz Perez MA; Dvorak CC; Egeler RM; Eldjerou L; Frangoul H; Guilcher GMT; Hayashi RJ; Ibrahim A; Kasow KA; Leung WH; Olsson RF; Pulsipher MA; Shah N; Shah NN; Thiel E; Talano JA; Kitko CL
Biol Blood Marrow Transplant; 2015 Dec; 21(12):2154-2159. PubMed ID: 26327632
[TBL] [Abstract][Full Text] [Related]
52. Detectable minimal residual disease before allogeneic hematopoietic stem cell transplantation predicts extremely poor prognosis in children with acute lymphoblastic leukemia.
Sramkova L; Muzikova K; Fronkova E; Krejci O; Sedlacek P; Formankova R; Mejstrikova E; Stary J; Trka J
Pediatr Blood Cancer; 2007 Jan; 48(1):93-100. PubMed ID: 16521130
[TBL] [Abstract][Full Text] [Related]
53. Successful Therapy Reduction and Intensification for Childhood Acute Lymphoblastic Leukemia Based on Minimal Residual Disease Monitoring: Study ALL10 From the Dutch Childhood Oncology Group.
Pieters R; de Groot-Kruseman H; Van der Velden V; Fiocco M; van den Berg H; de Bont E; Egeler RM; Hoogerbrugge P; Kaspers G; Van der Schoot E; De Haas V; Van Dongen J
J Clin Oncol; 2016 Aug; 34(22):2591-601. PubMed ID: 27269950
[TBL] [Abstract][Full Text] [Related]
54. [Lymphoblastic lymphoma and acute lymphoblastic leukemia: a clinicopathologic, immunophenotypic and prognostic study in 153 Chinese patients].
Pan Y; Li GD; Liu WP; Zhang WY; Tang Y; Li FY
Zhonghua Bing Li Xue Za Zhi; 2009 Dec; 38(12):810-5. PubMed ID: 20193455
[TBL] [Abstract][Full Text] [Related]
55. Update on biology and treatment of T-cell acute lymphoblastic leukaemia.
Patrick K; Vora A
Curr Opin Pediatr; 2015 Feb; 27(1):44-9. PubMed ID: 25502893
[TBL] [Abstract][Full Text] [Related]
56. Outcome of adults with relapsed/refractory T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma.
Samra B; Alotaibi AS; Short NJ; Khoury JD; Ravandi F; Garris R; Jain N; Konopleva M; Kantarjian H; Jabbour E
Am J Hematol; 2020 Sep; 95(9):E245-E247. PubMed ID: 32501545
[No Abstract] [Full Text] [Related]
57. The challenge to further improvements in survival of patients with T-ALL: Current treatments and new insights from disease pathogenesis.
O'Dwyer KM
Semin Hematol; 2020 Jul; 57(3):149-156. PubMed ID: 33256905
[TBL] [Abstract][Full Text] [Related]
58. Good prognosis or poor prognosis, dose-intensive or less intensive: who decides for adults with T-lymphoblastic lymphoma/leukemia.
Young KH
Leukemia; 2020 Nov; 34(11):3075-3076. PubMed ID: 32398791
[No Abstract] [Full Text] [Related]
59. ADAM28 overexpression regulated via the PI3K/Akt pathway is associated with relapse in de novo adult B-cell acute lymphoblastic leukemia.
Zhang XH; Wang CC; Jiang Q; Yang SM; Jiang H; Lu J; Wang QM; Feng FE; Zhu XL; Zhao T; Huang XJ
Leuk Res; 2015 Aug; ():. PubMed ID: 26340916
[TBL] [Abstract][Full Text] [Related]
60. T-Cell Acute Lymphoblastic Leukemia, Minimal Residual Disease, and Lymphocyte Recovery.
Naithani R; Abdelhaleem M; Punnett A
Pediatr Blood Cancer; 2016 May; 63(5):944. PubMed ID: 26728249
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
